LAST UPDATED: April 23, 2021, 7:31 p.m.
Pallavi Jha, New Delhi: There is good news regarding the coronavirus pandemic. The Drugs Controller General of India (DCGI) has approved Virafin of Zydus. This medicine is used in the treatment of coronavirus.
Zydus has claimed that 91.15% of coronavirus victims had RT-PCR test negative in just one day after the use of Virafin.
Virafin injection of Zydus Cadila will be used for adults who have coronavirus and have mild symptoms. The company claims that Virafin helps coronavirus patients recover quicker.
According to the company, if the drug is given at the beginning of the coronavirus infection, then it will help patients recover from the disease and will also reduce the discomfort. H
owever, this medicine will be given only after the advice of the doctor and the medicine will be available only in hospitals. The company had tried this drug at 25 centers, with good results.
Earlier, Zydus Cadila sought approval from the Drug Controller General of India (DGCI) for the treatment of Covid-19 regarding the drug PegiHep. The company had said that the drug Pegylated Interferon Alpha 2b or PegiHep proved to be effective by 91.15 percent.
The initial third-stage human trial yielded promising results from the drug. Interim results indicated that timely delivery of the drug may help patients recover more quickly and avoid the complication seen in the developing stages of the disease.